Ebos Group Limited · NZX:EBO
Ebos — UBS Australasia Conference 2016
14 slides from Ebos's conference presentation, Nov 7, 2016
Slide 1: UBS Australasia Conference Presentation
EBOS Group Limited For personal use only Presentation UBS Australasia Conference Patrick Davies Chief Executive Officer 7 November 2016
Slide 2: Important Information
Important Information The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary For personal use only form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness
Slide 3: EBOS Group - Snapshot
EBOS Group - Snapshot For personal use only EBOS Group is the Combined pharmacy and Hospital pharmaceutical hospital pharmaceutical wholesaler in Australia and largest and most wholesaler in Australia and New Zealand New Zealand No.1 No.1 diversified Australasian marketer, wholesaler and distributor
Slide 4: Overview
EBOS Group Overview Trans-Tasman Healthcare and Animal Care portfolio For personal use only ~$2.5 billion 42 Market capitalisation Locations in Australia and Dual listed on NZX and ASX New Zealand $7.1 billion 2,700+ FY16 revenue Employees Australia 79%, NZ 21% $225.5 million 38,000+ FY16 EBITDA Cus
Slide 5: Demonstrating strong growth
Demonstrating strong growth Revenue NPAT Earnings Per Share For personal use only NZ $m NZ $m Cents per share 7,101 127 84.0 6,068 11.1% 106 17.4% 15.7% 5,757 70.8 CAGR 92 CAGR CAGR 62.8 FY14 FY15 FY16 FY14 FY15 FY16 FY14 FY15 FY16 Operating Cash Flow Return on Capital Employed Dividends per share C
Slide 6: Overview - Market Channels
EBOS Group Overview - Market Channels For personal use only HEALTHCARE ANIMAL CARE Community Pharmacy & Institutional Multinational Pet Speciality, Pharmacy Grocery Healthcare Suppliers Grocery & Vet PHARMACY CONSUMER PHARMACEUTICAL CONTRACT PRODUCT WHOLESALE PRODUCTS LOGISTICS PRODUCT PHARMACY RETA
Slide 7: Business overview
Business overview ANIMAL CARE For personal use only 16% Animal Care 16% Consumer Products 6% Contract Pharmacy Logistics 49% 9% (Wholesale and Retail) HEALTHCARE Institutional 84% Healthcare 20% Data based on Gross Operating Revenue FY16 which comprises revenue less cost of sales and 7 write down of
Slide 8: Healthcare division
Healthcare division EBOS Group has a diversified trans-tasman portfolio with significant scale For personal use only that offers multiple solutions to customers and end-consumers COMMUNITY CONSUMER INSTITUTIONAL CONTRACT PHARMACY PRODUCTS HEALTHCARE LOGISTICS Key themes: Healthcare • An ageing popul
Slide 9: Retail Pharmacy
Retail Pharmacy A key provider of support services to retail pharmacy in Australia and New For personal use only Zealand. – Industry is seeing continuing consolidation – Majority shareholder in the newly merged Chemmart & Terry White Group. The merger will create one of Australia’s largest retail ph
Slide 10: Investing in our distribution network
Investing in our distribution network • EBOS Group is committed to on-going investment in our distribution network to For personal use only maintain a state-of- the-art distribution network • Technology increases productivity and helps ensure all customers and end- consumer demands and requirements
Slide 11: Animal care division
Animal care division Comprehensive distribution network in the animal care market, with pet brands, specialty retail outlets and a leading veterinary wholesaler For personal use only PRODUCT RETAIL VET WHOLESALE Developing and growing our own 50% owner of Animates in NZ Number 2 Vet Wholesaler in br
Slide 12: Strategic approach
EBOS Group strategic approach Our Healthcare and Animal Care strategic focus is centred on For personal use only Leading Market Disciplined Capital Investing for Growth Positions Management Two types of investments: We aim to have positions of • Cash generation to drive scope scale in the markets we
Slide 13: FY17 outlook
FY17 outlook As recently stated at our Annual meeting on 19 October 2016, we have For personal use only • made a positive start to the first quarter of FY17, notwithstanding the higher NZD:AUD exchange rate which has been evident. • On the basis of our current trading performance we expect constant
Slide 14: End
For personal use only End contact Mark Connell Group Treasurer and Investor Relations Manager EBOS Group Limited mobile +61 402 995519 email mark.connell@ebosgroup.com